Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity

[1]  P. Almgren,et al.  A variation in 3' UTR of hPTP1B increases specific gene expression and associates with insulin resistance. , 2002, American journal of human genetics.

[2]  M. Ott,et al.  A semi‐automated system for analysis and storage of SNPs , 2001, Human mutation.

[3]  J. Ott,et al.  Selecting SNPs in two‐stage analysis of disease association data: a model‐free approach , 2000, Annals of human genetics.

[4]  F. Assal,et al.  Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations. , 2000, Digestive diseases and sciences.

[5]  C. Warren Olanow,et al.  Tolcapone and Hepatotoxic Effects , 2000 .

[6]  R. Gasser,et al.  Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase. , 1999, British journal of clinical pharmacology.

[7]  R Higuchi,et al.  Single-tube genotyping without oligonucleotide probes. , 1999, Genome research.

[8]  F. Assal,et al.  Tolcapone and fulminant hepatitis , 1998, The Lancet.

[9]  M. Ciotti,et al.  Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. , 1997, Pharmacogenetics.

[10]  D. Birch,et al.  Simplified hot start PCR , 1996, Nature.

[11]  J. Hartley,et al.  Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. , 1990, Gene.

[12]  A. Clark,et al.  Inference of haplotypes from PCR-amplified samples of diploid populations. , 1990, Molecular biology and evolution.

[13]  W. Hillis,et al.  Cardiovascular effects of a new inotropic agent, U. K. 14275, in patients with coronary heart disease. , 1977, British journal of clinical pharmacology.